Navigation Links
Commercialization of drugs by fast tracking is a cause of concern

A senior doctor has by the means of BMJ raised a serious concern over licensing of new drugs for commercialization purposes. //

This has come after natalizumab, a new drug for multiple sclerosis, was approved and thereafter recalled after three months. This was done after three trial patients developed a life threatening condition while being treated.

The drug was licensed by the US Food and Drug Administration in 2004 on the basis of short term results from two unpublished trials. The result was that when tested it was on 28 February 2005, recalled after three trial patients developed progressive multifocal leucoencephalopathy (PML). The result was that in between two of the patients died.

The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the FDA for commercial licensing. This was brought to the fore by consultant neurologist Abhijit Chaudhuri.

The warning signal is here and it must be paid heed to so that in the future such mistakes are not repeated.


'"/>




Page: 1

Related medicine news :

1. Commercialization of Biotech Discoveries, An Encouragement For Researchers
2. Cancer drugs in development nearly doubled since 1995
3. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
4. African HIV strains more resistant to anti HIV drugs
5. Right drugs drastically cut stroke risk
6. Relating heart protection and antihypertensive drugs
7. Enzyme may be target for obesity drugs
8. New HIV cases resist drugs
9. Relief to pregnant women using fertility drugs
10. AIDS drugs linked to heart attack risk
11. FDA debates status of decongestant drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... 23, 2017 , ... DMG Productions is proud to announce ... scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will ... address the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... organization in North America for the scientific development, healthcare training and clinical application ... Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... text with video footage. ProRandom works by using a virtual camera to create the ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/22/2017)... ... , ... Phytocéane invites clients to take an exotic journey deep into the ... MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast ... coral to create this gentle, velvety body cream to envelop the skin in moisture ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... InDex Pharmaceuticals Holding AB (publ) today announced ... of the European Crohn,s and Colitis Organisation (ECCO). The ECCO congress ... on inflammatory bowel disease (IBD). The congress is held in ... ... again having been selected to present data at the largest IBD ...
(Date:1/21/2017)... , Jan. 20, 2017 ResMed (NYSE: ... Medical ( Winter Haven, Florida ) today announced they ... parties. BMC and 3B will be permitted to sell their existing ... make a one-time settlement payment to 3B to close the ... did not include an admission of liability or wrongdoing by any ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... Trends - Technology, Route Of Administration, End User - Forecast to ... ... to grow at a CAGR of around 7.8% over the next ... This industry report analyzes the global markets for Advanced Drug Delivery ...
Breaking Medicine Technology: